{"id":50743,"date":"2022-11-10T23:02:44","date_gmt":"2022-11-10T22:02:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-change-to-its-board-of-directors\/"},"modified":"2022-11-10T23:02:44","modified_gmt":"2022-11-10T22:02:44","slug":"precision-biosciences-announces-change-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-change-to-its-board-of-directors\/","title":{"rendered":"Precision BioSciences Announces Change to its Board of Directors"},"content":{"rendered":"
\n

\n– Raymond F. Schinazi, Ph.D., to Step Down from Board of Directors and Continue as a Member of the Company\u2019s Scientific Advisory Board (SAB)<\/i>\n<\/p>\n

DURHAM, N.C.–(BUSINESS WIRE)–$DTIL<\/a> #ARCUS<\/a>–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS\u00ae-based ex vivo<\/i> allogeneic CAR T and in vivo<\/i> gene editing therapies, today announced that Dr. Raymond Schinazi is stepping down from the company\u2019s Board of Directors and will continue as a member of the company\u2019s SAB, lending his deep expertise in antiviral drug discovery and development.\n<\/p>\n

<\/a><\/p>\n

\n\u201cRay is a trusted advisor, and since early 2019 when he joined the Board, has provided Precision with incredible perspective and support for the company\u2019s CAR T and in vivo<\/i> gene editing pipeline, particularly the development of ARCUS nucleases as an in vivo<\/i> gene editing strategy to deliver a potential functional cure for chronic hepatitis B,\u201d said Kevin Buehler, Chairman of the Board. \u201cWhile we will miss having Ray on the Board, we look forward to continuing working with him as a SAB member. This change provides the opportunity for us to continue refreshing our Board with new independent directors that bring additional diverse experience and relevant expertise to Precision.\u201d\n<\/p>\n

\n\u201cI\u2019d like to thank Precision for the opportunity to work with an incredible team and a gene editing industry leader focused on developing potentially transformative treatment and curative options for high unmet needs,\u201d said Dr. Schinazi. \u201cI am confident the company will have continued success and I look forward to focusing my efforts on Precision\u2019s SAB to further contribute to the development of its innovative in vivo<\/i> pipeline, including a new, much-needed and potentially curative modality for chronic hepatitis B.\u201d\n<\/p>\n

\nDr. Schinazi\u2019s resignation from the Board of Directors was effective as of November 5, 2022.\n<\/p>\n

\nAbout Precision BioSciences, Inc.<\/b>\n<\/p>\n

\nPrecision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS\u00ae genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the company\u2019s pipeline consists of multiple ex vivo<\/i> \u201coff-the-shelf\u201d CAR T immunotherapy clinical candidates and several in vivo<\/i> gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com<\/a>.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the development and potential efficacy of Precision\u2019s product candidates and potential functional cure for chronic hepatitis B. In some cases, you can identify forward-looking statements by terms such as \u201caim,\u201d \u201canticipate,\u201d \u201capproach,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201clook,\u201d \u201cmay,\u201d \u201cmission,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative thereof and similar words and expressions.\n<\/p>\n

\nForward-looking statements are based on management\u2019s current expectations, beliefs and assumptions and on information currently available to Precision. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: Precision\u2019s ability to become profitable; Precision\u2019s ability to procure sufficient funding and requirements under its current debt instruments and effects of restrictions thereunder; risks associated with raising additional capital; Precision\u2019s operating expenses and its ability to predict what those expenses will be; Precision\u2019s limited operating history; the success of its programs and product candidates in which it expends its resources; Precision\u2019s limited ability or inability to assess the safety and efficacy of its product candidates; Precision\u2019s dependence on its ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities, preclinical studies and clinical trials; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, and biotechnology fields; Precision\u2019s or its collaborators\u2019 ability to identify, develop and commercialize product candidates; and other important factors discussed under the caption \u201cRisk Factors\u201d in Precision\u2019s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, filed with the SEC, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC\u2019s website at www.sec.gov<\/a> and the Investors page of Precision\u2019s website under SEC Filings at investor.precisionbiosciences.com.\n<\/p>\n

\nAll forward-looking statements speak only as of the date of this press release and, except as required by applicable law, Precision has no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:<\/b>
Mei Burris
\n
Director, Investor Relations and Finance
\n
Mei.Burris@precisionbiosciences.com<\/a><\/p>\n

Media Contact:<\/b>
Maurissa Messier
\n
Senior Director, Corporate Communications
\n
Maurissa.Messier@precisionbiosciences.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

– Raymond F. Schinazi, Ph.D., to Step Down from Board of Directors and Continue as a Member of the Company\u2019s Scientific Advisory Board (SAB) DURHAM, N.C.–(BUSINESS WIRE)–$DTIL #ARCUS–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS\u00ae-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Dr. … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50743","6":"format-standard","7":"category-industry"},"yoast_head":"\nPrecision BioSciences Announces Change to its Board of Directors - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-change-to-its-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Precision BioSciences Announces Change to its Board of Directors - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"– Raymond F. Schinazi, Ph.D., to Step Down from Board of Directors and Continue as a Member of the Company\u2019s Scientific Advisory Board (SAB) DURHAM, N.C.–(BUSINESS WIRE)–$DTIL #ARCUS–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS\u00ae-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Dr. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-change-to-its-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-10T22:02:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221110006055\/en\/593587\/21\/Precision_BioSciences_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-change-to-its-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-change-to-its-board-of-directors\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Precision BioSciences Announces Change to its Board of Directors\",\"datePublished\":\"2022-11-10T22:02:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-change-to-its-board-of-directors\\\/\"},\"wordCount\":855,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-change-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221110006055\\\/en\\\/593587\\\/21\\\/Precision_BioSciences_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-change-to-its-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-change-to-its-board-of-directors\\\/\",\"name\":\"Precision BioSciences Announces Change to its Board of Directors - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-change-to-its-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-change-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221110006055\\\/en\\\/593587\\\/21\\\/Precision_BioSciences_logo.jpg\",\"datePublished\":\"2022-11-10T22:02:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-change-to-its-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-change-to-its-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-change-to-its-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221110006055\\\/en\\\/593587\\\/21\\\/Precision_BioSciences_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221110006055\\\/en\\\/593587\\\/21\\\/Precision_BioSciences_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-change-to-its-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Precision BioSciences Announces Change to its Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Precision BioSciences Announces Change to its Board of Directors - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-change-to-its-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Precision BioSciences Announces Change to its Board of Directors - Pharma Trend","og_description":"– Raymond F. Schinazi, Ph.D., to Step Down from Board of Directors and Continue as a Member of the Company\u2019s Scientific Advisory Board (SAB) DURHAM, N.C.–(BUSINESS WIRE)–$DTIL #ARCUS–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS\u00ae-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Dr. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-change-to-its-board-of-directors\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-10T22:02:44+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221110006055\/en\/593587\/21\/Precision_BioSciences_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-change-to-its-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-change-to-its-board-of-directors\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Precision BioSciences Announces Change to its Board of Directors","datePublished":"2022-11-10T22:02:44+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-change-to-its-board-of-directors\/"},"wordCount":855,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-change-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221110006055\/en\/593587\/21\/Precision_BioSciences_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-change-to-its-board-of-directors\/","url":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-change-to-its-board-of-directors\/","name":"Precision BioSciences Announces Change to its Board of Directors - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-change-to-its-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-change-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221110006055\/en\/593587\/21\/Precision_BioSciences_logo.jpg","datePublished":"2022-11-10T22:02:44+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-change-to-its-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-change-to-its-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-change-to-its-board-of-directors\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221110006055\/en\/593587\/21\/Precision_BioSciences_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221110006055\/en\/593587\/21\/Precision_BioSciences_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-change-to-its-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Precision BioSciences Announces Change to its Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50743"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50743\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}